Projectes

Codi

2024 FI-1 00075

Investigador/a principal

Daniel Natera de Benito

Rol

Individual

Any d'inici

2024

Any de finalització

2027

Import total

73081,31€

Objectius

AGAUR_Daniel Natera

Codi

CPP2023-010478

Investigador/a principal

Jaume Mora Graupera

Rol

Participant

Any d'inici

2024

Any de finalització

2027

Import total

730306€

Objectius

MINISTERIO DE CIENCIA E INNOVACIÓN_Jaume Mora Graupera

Codi

101140815

Investigador/a principal

Marcos Febas Fernández

Rol

Participant

Any d'inici

2024

Any de finalització

2026

Import total

169581,41€

Objectius

N.E.A.R. to Guardians general objective is to increase the networking, exchange of good practices, and knowledge sharing, amongst various relevant actors across the EU on reinforcing effective guardianship with the aim of ensuring full access of basic rights and
potential of UASCs, focusing in key areas for integration such as housing, working inclusion and education, in 5 EU Member States
(Italy, Spain, Greece, Slovenia and Belgium). Target group will be the guardians of UASCs and the relevant actors providing support to guardians, such as public administrations
and institutions, ministries/authorities for children or social affairs, international organisations, social services responsible for housing,
labour market integration, education.
Main project activities will be: a collection and exchange of good practices, including study visits, on effective guardianship to UASCs in the key areas of housing, labour market integration, education, in 5 MS (WP2); a training curriculum focused in the key areas
mentioned above, and an e-learning platform and digital library for guardians and relevant stakeholders (WP3); 4 local working tables (in Italy, Greece, Spain, Slovenia) to consolidate methodologies and strengthening local networks, and the creation of a “Sister cities
Network” and a “Manifesto for Inclusion” which will ensure the continuation of the comparison and exchange activities over the years. A set of tailor-made awareness raising activities, advocacy, dissemination and communication measures (WP5) will be carried
out to maximize the project results.
The expected impacts are: a reinforced capacity of institutions involved in reception, protection and guardianship, and of guardians, in protection of UASCs; a better dialogue among different groups of society, institutions and local authorities on effective
guardianship; an increased level of inclusion and protection of young migrants in host EU society; increased visibility of guardianship across all MS.

Codi

FI23/00015

Investigador/a principal

Josep Maria Haro Abad

Rol

Individual

Any d'inici

2024

Any de finalització

2028

Import total

89900€

Objectius

ISCIII_Josep Maria Haro

Codi

CD23/00010

Investigador/a principal

Josep Maria Haro Abad

Rol

Individual

Any d'inici

2024

Any de finalització

2027

Import total

95000€

Objectius

ISCIII_Josep Maria Haro

Codi

101136670

Investigador/a principal

Andrés Morales La Madrid

Rol

Participant

Any d'inici

2024

Any de finalització

2028

Import total

197500€

Objectius

Here's a concise summary of the GLIOMATCH project:The GLIOMATCH project aims to improve clinical outcomes for glioblastoma (GBM) and paediatric high-grade glioma (pHGG) patients by enabling immunology-based patient stratification to personalize immunotherapy selection and track treatment efficacy. Given the heterogeneity and plasticity of these tumors, past clinical trials have largely failed, and biomarkers for predicting and monitoring immunotherapy responses remain scarce.
GLIOMATCH will integrate spatially resolved single-cell multiomics data with non-invasive MRI imaging, creating an MRI Radio-multiomics hub for clinicians. This tool will allow for patient stratification, therapy matching, and real-time treatment monitoring.
The project will analyze the largest immuno-oncology-treated GBM/pHGG cohort (n>300), matched controls (n>300), and long-term survivors (n~140) to understand how tumor-host interactions influence immunotherapy responses. A UNCAN-compatible data lake will facilitate continuous data collection and machine learning model refinement, further advancing precision medicine and novel therapeutic strategies.

Codi

PI24/00469

Investigador/a principal

MªAngels García Cazorla, Alfonso Luis De Oyarzabal Sanz

Rol

Individual

Any d'inici

2024

Any de finalització

2027

Import total

283750€

Objectius

ISCIII_Àngels Garcia Cazorla

Codi

ICI23/00063

Investigador/a principal

Andrés Morales La Madrid

Rol

Individual

Any d'inici

2024

Any de finalització

2027

Import total

2030148,99€

Objectius

Diffuse intrinsic pontine glioma (DIPG) is an incurable pediatric brain tumor. It is considered an orphan disease with no meaningful therapeutic advances in the last decades. Tumor irradiation is the only treatment that delays tumor progression, with most patients dying within two years from diagnosis. Advanced therapies, including immunotherapy (IT), offer a novel and promising approach with the hope that combining more than one IT will be similarly tolerated and potentially more efficacious for this fragile cohort of patients. We have demonstrated the feasibility and safety of the administration of dendritic cell (DC) vaccines in patients with DIPG¹.
Of note, these vaccines were capable of generating a robust immune response detected in both peripheral blood (PB) and cerebrospinal fluid (CSF). More recently, systemic and intraventricular administration of CART against a variety of targets has been shown to be safe and capable of generating a significant immune response. IL13Ra2 is a promising and established target in brain tumors (including DIPG). We propose an advanced therapy phase Ib clinical trial aimed at patients with newly diagnosed DIPG: intradermal vaccination with 5 doses of pulsed CD with tumor lysates, followed by intraventricular infusion of CART anti-IL13Ra2. Subsequently, patients will receive 3 additional maintenance doses of tumor lysate, as per our trial NCT02840123.
Both cellular products, DC vaccines and CART anti-IL13Ra2, meet the criteria of orphan medications with high health care system interest and no commercial interest (Artículo 3 del Real Decreto Legislativo 1/2015, de 24 de julio). If well tolerated and efficacious, this approach could be explored in other brain and spine aggressive gliomas. Importantly, patients with DIPG are under-represented in pharma-sponsored clinical trials

Codi

FI23/00064

Investigador/a principal

Janet Hoenicka

Rol

Individual

Any d'inici

2024

Any de finalització

2027

Import total

89900€

Objectius

ISCIII_Janet Hoenicka

Codi

FI23/00316

Investigador/a principal

Francesca Crovetto

Rol

Individual

Any d'inici

2024

Any de finalització

2027

Import total

119567€

Objectius

ISCIII_Francesca Crovetto